Erasca (ERAS) Cash & Equivalents (2020 - 2026)
Erasca (ERAS) posted Cash & Equivalents of $47.3 million for Q1 2026, down 35.97% on a QoQ basis from $73.8 million in Q4 2025, and down 32.95% year-over-year from $70.5 million in Q1 2025.
Erasca (ERAS) Cash & Equivalents (2020 - 2026) Analysis & Trends
Erasca's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.
- Quarterly Cash & Equivalents fell 32.95% year-over-year to $47.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.3 million (down 32.95% YoY) and the FY2025 annual result came in at $73.8 million, up 8.95% from the prior year.
- Cash & Equivalents was $47.3 million for Q1 2026 at Erasca, down from $73.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $333.3 million in Q1 2022 and bottomed at $47.3 million in Q1 2026.
- A 5-year average of $146.1 million and a median of $112.9 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 96.1% — and 2023, when it sank 67.25%.
- Erasca's Cash & Equivalents stood at $284.2 million in 2022, then sank by 67.25% to $93.1 million in 2023, then decreased by 27.22% to $67.7 million in 2024, then gained by 8.95% to $73.8 million in 2025, then tumbled by 35.97% to $47.3 million in 2026.
- Business Quant data shows ERAS's Cash & Equivalents at $47.3 million in Q1 2026, $73.8 million in Q4 2025, and $70.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 47.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.26 Mn |
| Dec 31, 2025 | 73.81 Mn |
| Sep 30, 2025 | 70.23 Mn |
| Jun 30, 2025 | 66.14 Mn |
| Mar 31, 2025 | 70.48 Mn |
| Dec 31, 2024 | 67.74 Mn |
| Sep 30, 2024 | 68.89 Mn |
| Jun 30, 2024 | 172.80 Mn |
| Mar 31, 2024 | 172.80 Mn |
| Dec 31, 2023 | 93.08 Mn |
| Sep 30, 2023 | 112.86 Mn |
| Jun 30, 2023 | 138.79 Mn |
| Mar 31, 2023 | 272.76 Mn |
| Dec 31, 2022 | 284.22 Mn |
| Sep 30, 2022 | 219.26 Mn |
| Jun 30, 2022 | 219.26 Mn |
| Mar 31, 2022 | 333.35 Mn |
| Dec 31, 2021 | 360.49 Mn |
| Sep 30, 2021 | 445.81 Mn |
| Jun 30, 2021 | 156.40 Mn |